Targeted alpha therapy of ovarian cancer with 212Pb-labeled anti-PTK7 antibody: On-site 212Pb production and preclinical insights

Yani Berckmans, Roxanne Wouters, Zeljka Raskovic-Lovre, Sara Van Mechelen, Kim Lindland, Tina Bønsdorff, An Coosemans, Frederik Cleeren

Open source

DOI
10.1016/j.nucmedbio.2025.109570
Published
2025-11
Container
Nuclear Medicine and Biology
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.nucmedbio.2025.109570,
  title = {Targeted alpha therapy of ovarian cancer with 212Pb-labeled anti-PTK7 antibody: On-site 212Pb production and preclinical insights},
  author = {Yani Berckmans and Roxanne Wouters and Zeljka Raskovic-Lovre and Sara Van Mechelen and Kim Lindland and Tina Bønsdorff and An Coosemans and Frederik Cleeren},
  year = {2025},
  journal = {Nuclear Medicine and Biology},
  doi = {10.1016/j.nucmedbio.2025.109570},
  url = {https://doi.org/10.1016/j.nucmedbio.2025.109570}
}

RIS

TY  - JOUR
TI  - Targeted alpha therapy of ovarian cancer with 212Pb-labeled anti-PTK7 antibody: On-site 212Pb production and preclinical insights
AU  - Yani Berckmans
AU  - Roxanne Wouters
AU  - Zeljka Raskovic-Lovre
AU  - Sara Van Mechelen
AU  - Kim Lindland
AU  - Tina Bønsdorff
AU  - An Coosemans
AU  - Frederik Cleeren
PY  - 2025
JO  - Nuclear Medicine and Biology
DO  - 10.1016/j.nucmedbio.2025.109570
UR  - https://doi.org/10.1016/j.nucmedbio.2025.109570
ER  - 

APA

Berckmans, Y., Wouters, R., Raskovic-Lovre, Z., Mechelen, S. V., Lindland, K., Bønsdorff, T., Coosemans, A., & Cleeren, F. (2025). Targeted alpha therapy of ovarian cancer with 212Pb-labeled anti-PTK7 antibody: On-site 212Pb production and preclinical insights. Nuclear Medicine and Biology. https://doi.org/10.1016/j.nucmedbio.2025.109570

Source records